HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies

Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.

Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17
Alex Azar testifies at his confirmation hearing before the Senate HELP Committee on Nov. 29, 2017.

Now that his nomination to be HHS secretary has cleared the full Senate, Alex Azar is likely to focus on advancing the government's development of policies to reduce drug prices in Medicare Part D and Part B.

Azar's nomination was approved by the Senate in a 55-43 vote, with support from five Democrats and one Independent. (See...

More from Pricing Debate

‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe

 

Executive Summary: European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By 

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.

More from Market Access

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

Saving Part D: US Medicare Advisors Sound The Alarm

 

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.